Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?

× No keyword cloud information.

8 in total

1. Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial.

Authors: Hye Rim Na; O Sung Kwon; Joon Kyu Kang; Yong Han Kim; Ju Yong Lim
Journal: Trials Date: 2022-05-23 Impact factor: 2.728

Review 2. Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors: Anwar Santoso; Yulianto Yulianto; Hendra Simarmata; Abhirama Nofandra Putra; Erlin Listiyaningsih
Journal: Int J Angiol Date: 2021-02-18

Review 3. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering.

Authors: Dhrubajyoti Bandyopadhyay; Kumar Ashish; Adrija Hajra; Arshna Qureshi; Raktim K Ghosh
Journal: J Lipids Date: 2018-03-25

4. Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders.

Authors: Falk W Lohoff
Journal: Int J Neuropsychopharmacol Date: 2018-12-01 Impact factor: 5.176

5. Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids.

Authors: Laurent Vachon; Ali Smaani; Nolwenn Tessier; Gabriel Jean; Annie Demers; Andreea Milasan; Nadine Ardo; Stéphanie Jarry; Louis Villeneuve; Azadeh Alikashani; Vincent Finherty; Matthieu Ruiz; Mary G Sorci-Thomas; Gaétan Mayer; Catherine Martel
Journal: Theranostics Date: 2022-01-01 Impact factor: 11.556

6. Anti-PCSK9 monoclonal antibody attenuates high-fat diet and zymosan-induced vascular inflammation in C57BL/6 mice by modulating TLR2/NF-ƙB signaling pathway.

Authors: Priyanka Arya; Uma Bhandari; Kalicharan Sharma; Priyanka Bansal
Journal: Iran J Basic Med Sci Date: 2022-05 Impact factor: 2.532

Review 7. Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia.

Authors: Piotr Pęczek; Mateusz Leśniewski; Tomasz Mazurek; Lukasz Szarpak; Krzysztof J Filipiak; Aleksandra Gąsecka
Journal: Life (Basel) Date: 2021-05-23

8. PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.

Authors: Ji Soo Lee; Partha Mukhopadhyay; Csaba Matyas; Eszter Trojnar; Janos Paloczi; Yuan Ru Yang; Brandon A Blank; Cody Savage; Alexander V Sorokin; Nehal N Mehta; Janaina C M Vendruscolo; George F Koob; Leandro F Vendruscolo; Pal Pacher; Falk W Lohoff
Journal: Sci Rep Date: 2019-11-20 Impact factor: 4.379

8 in total